nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ABL1—esophageal cancer	0.235	0.407	CbGaD
Vandetanib—KDR—esophageal cancer	0.199	0.346	CbGaD
Vandetanib—EGFR—esophageal cancer	0.143	0.247	CbGaD
Vandetanib—ABCG2—Carboplatin—esophageal cancer	0.0197	0.276	CbGbCtD
Vandetanib—ABCG2—Cisplatin—esophageal cancer	0.0168	0.236	CbGbCtD
Vandetanib—ABCC1—Methotrexate—esophageal cancer	0.0163	0.229	CbGbCtD
Vandetanib—ABCG2—Methotrexate—esophageal cancer	0.0109	0.153	CbGbCtD
Vandetanib—ALB—Methotrexate—esophageal cancer	0.00754	0.106	CbGbCtD
Vandetanib—ERBB3—exocrine gland—esophageal cancer	0.00198	0.0231	CbGeAlD
Vandetanib—PTK6—bronchus—esophageal cancer	0.00149	0.0174	CbGeAlD
Vandetanib—PTK6—trachea—esophageal cancer	0.00134	0.0156	CbGeAlD
Vandetanib—RET—neck—esophageal cancer	0.00117	0.0137	CbGeAlD
Vandetanib—PTK6—digestive system—esophageal cancer	0.00115	0.0135	CbGeAlD
Vandetanib—BMPR1B—epithelium—esophageal cancer	0.00115	0.0134	CbGeAlD
Vandetanib—BMPR1B—bronchus—esophageal cancer	0.00113	0.0132	CbGeAlD
Vandetanib—Gefitinib—SBK1—esophageal cancer	0.00111	0.136	CrCbGaD
Vandetanib—Bosutinib—CSNK1A1—esophageal cancer	0.00109	0.134	CrCbGaD
Vandetanib—LTK—lung—esophageal cancer	0.001	0.0117	CbGeAlD
Vandetanib—PTK6—lung—esophageal cancer	0.000961	0.0112	CbGeAlD
Vandetanib—FLT4—epithelium—esophageal cancer	0.000904	0.0106	CbGeAlD
Vandetanib—RIPK2—epithelium—esophageal cancer	0.000899	0.0105	CbGeAlD
Vandetanib—EPHA5—digestive system—esophageal cancer	0.00089	0.0104	CbGeAlD
Vandetanib—RIPK2—bronchus—esophageal cancer	0.000885	0.0104	CbGeAlD
Vandetanib—VEGFA—bronchus—esophageal cancer	0.000883	0.0103	CbGeAlD
Vandetanib—KDR—neck—esophageal cancer	0.000873	0.0102	CbGeAlD
Vandetanib—IRAK4—bronchus—esophageal cancer	0.000864	0.0101	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—esophageal cancer	0.000864	0.0101	CbGeAlD
Vandetanib—ERBB3—epithelium—esophageal cancer	0.00086	0.0101	CbGeAlD
Vandetanib—Afatinib—ERBB2—esophageal cancer	0.000829	0.102	CrCbGaD
Vandetanib—RET—epithelium—esophageal cancer	0.000798	0.00933	CbGeAlD
Vandetanib—MKNK1—bronchus—esophageal cancer	0.000795	0.0093	CbGeAlD
Vandetanib—RIPK2—trachea—esophageal cancer	0.000795	0.00929	CbGeAlD
Vandetanib—VEGFA—trachea—esophageal cancer	0.000793	0.00927	CbGeAlD
Vandetanib—PLK4—lung—esophageal cancer	0.000791	0.00926	CbGeAlD
Vandetanib—FMO1—trachea—esophageal cancer	0.000788	0.00922	CbGeAlD
Vandetanib—LCK—bronchus—esophageal cancer	0.000786	0.00919	CbGeAlD
Vandetanib—IRAK4—trachea—esophageal cancer	0.000776	0.00908	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—esophageal cancer	0.000766	0.00895	CbGeAlD
Vandetanib—ERBB3—trachea—esophageal cancer	0.000761	0.0089	CbGeAlD
Vandetanib—FMO3—bronchus—esophageal cancer	0.000759	0.00887	CbGeAlD
Vandetanib—Bosutinib—MAP3K3—esophageal cancer	0.000759	0.0929	CrCbGaD
Vandetanib—PDGFRB—neck—esophageal cancer	0.000755	0.00884	CbGeAlD
Vandetanib—SLK—bronchus—esophageal cancer	0.000753	0.00881	CbGeAlD
Vandetanib—FYN—bronchus—esophageal cancer	0.000732	0.00857	CbGeAlD
Vandetanib—BMPR1B—lung—esophageal cancer	0.000728	0.00852	CbGeAlD
Vandetanib—MAP3K19—lung—esophageal cancer	0.000728	0.00852	CbGeAlD
Vandetanib—TEK—epithelium—esophageal cancer	0.000727	0.0085	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—esophageal cancer	0.000717	0.00838	CbGeAlD
Vandetanib—MAP4K5—bronchus—esophageal cancer	0.000716	0.00837	CbGeAlD
Vandetanib—TEK—bronchus—esophageal cancer	0.000716	0.00837	CbGeAlD
Vandetanib—LCK—trachea—esophageal cancer	0.000705	0.00825	CbGeAlD
Vandetanib—AXL—trachea—esophageal cancer	0.000703	0.00822	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—esophageal cancer	0.0007	0.00819	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—esophageal cancer	0.0007	0.00819	CbGeAlD
Vandetanib—BLK—lymph node—esophageal cancer	0.000693	0.00811	CbGeAlD
Vandetanib—LTK—lymph node—esophageal cancer	0.000686	0.00802	CbGeAlD
Vandetanib—EPHB6—bronchus—esophageal cancer	0.000684	0.008	CbGeAlD
Vandetanib—RIPK2—digestive system—esophageal cancer	0.000684	0.008	CbGeAlD
Vandetanib—FMO1—digestive system—esophageal cancer	0.000678	0.00793	CbGeAlD
Vandetanib—SLK—trachea—esophageal cancer	0.000676	0.00791	CbGeAlD
Vandetanib—YES1—bronchus—esophageal cancer	0.000661	0.00773	CbGeAlD
Vandetanib—Mucosal inflammation—Capecitabine—esophageal cancer	0.00066	0.00762	CcSEcCtD
Vandetanib—FYN—trachea—esophageal cancer	0.000658	0.00769	CbGeAlD
Vandetanib—STK10—bronchus—esophageal cancer	0.000655	0.00766	CbGeAlD
Vandetanib—ERBB3—digestive system—esophageal cancer	0.000654	0.00765	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—esophageal cancer	0.000647	0.00756	CbGeAlD
Vandetanib—SRC—epithelium—esophageal cancer	0.000646	0.00755	CbGeAlD
Vandetanib—Afatinib—ABL1—esophageal cancer	0.000645	0.079	CrCbGaD
Vandetanib—MAP4K5—trachea—esophageal cancer	0.000643	0.00752	CbGeAlD
Vandetanib—FLT3—lung—esophageal cancer	0.000632	0.00739	CbGeAlD
Vandetanib—Pericarditis—Methotrexate—esophageal cancer	0.000629	0.00726	CcSEcCtD
Vandetanib—Impaired healing—Methotrexate—esophageal cancer	0.000629	0.00726	CcSEcCtD
Vandetanib—SRC—smooth muscle tissue—esophageal cancer	0.000622	0.00728	CbGeAlD
Vandetanib—STK35—lung—esophageal cancer	0.000619	0.00724	CbGeAlD
Vandetanib—MKNK1—digestive system—esophageal cancer	0.000614	0.00719	CbGeAlD
Vandetanib—Platelet count decreased—Capecitabine—esophageal cancer	0.000614	0.00709	CcSEcCtD
Vandetanib—Visual acuity reduced—Capecitabine—esophageal cancer	0.000614	0.00709	CcSEcCtD
Vandetanib—EPHB6—trachea—esophageal cancer	0.000614	0.00718	CbGeAlD
Vandetanib—RET—digestive system—esophageal cancer	0.000607	0.0071	CbGeAlD
Vandetanib—FGR—digestive system—esophageal cancer	0.000607	0.0071	CbGeAlD
Vandetanib—ABL2—lung—esophageal cancer	0.000603	0.00706	CbGeAlD
Vandetanib—Infection—Carboplatin—esophageal cancer	0.000599	0.00692	CcSEcCtD
Vandetanib—Serum creatinine increased—Capecitabine—esophageal cancer	0.000594	0.00686	CcSEcCtD
Vandetanib—KDR—epithelium—esophageal cancer	0.000594	0.00695	CbGeAlD
Vandetanib—YES1—trachea—esophageal cancer	0.000593	0.00694	CbGeAlD
Vandetanib—EGFR—lung—esophageal cancer	0.000589	0.00689	CbGeAlD
Vandetanib—MAP2K5—bronchus—esophageal cancer	0.000585	0.00684	CbGeAlD
Vandetanib—KDR—bronchus—esophageal cancer	0.000585	0.00684	CbGeAlD
Vandetanib—Hypomagnesaemia—Capecitabine—esophageal cancer	0.000575	0.00664	CcSEcCtD
Vandetanib—FLT4—lung—esophageal cancer	0.000574	0.00672	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—esophageal cancer	0.000572	0.00669	CbGeAlD
Vandetanib—Nephropathy—Methotrexate—esophageal cancer	0.000571	0.0066	CcSEcCtD
Vandetanib—RIPK2—lung—esophageal cancer	0.000571	0.00668	CbGeAlD
Vandetanib—VEGFA—lung—esophageal cancer	0.000569	0.00666	CbGeAlD
Vandetanib—Hypothyroidism—Capecitabine—esophageal cancer	0.000569	0.00657	CcSEcCtD
Vandetanib—FMO1—lung—esophageal cancer	0.000566	0.00662	CbGeAlD
Vandetanib—FYN—digestive system—esophageal cancer	0.000566	0.00662	CbGeAlD
Vandetanib—Nail disorder—Capecitabine—esophageal cancer	0.000563	0.0065	CcSEcCtD
Vandetanib—IRAK4—lung—esophageal cancer	0.000558	0.00652	CbGeAlD
Vandetanib—Furuncle—Methotrexate—esophageal cancer	0.000555	0.0064	CcSEcCtD
Vandetanib—ERBB3—lung—esophageal cancer	0.000547	0.00639	CbGeAlD
Vandetanib—Cellulitis—Cisplatin—esophageal cancer	0.000545	0.00629	CcSEcCtD
Vandetanib—PLK4—lymph node—esophageal cancer	0.000541	0.00633	CbGeAlD
Vandetanib—Sudden death—Methotrexate—esophageal cancer	0.000532	0.00614	CcSEcCtD
Vandetanib—Haemoglobin decreased—Capecitabine—esophageal cancer	0.000531	0.00613	CcSEcCtD
Vandetanib—Hypercalcaemia—Capecitabine—esophageal cancer	0.000526	0.00607	CcSEcCtD
Vandetanib—MAP2K5—trachea—esophageal cancer	0.000525	0.00614	CbGeAlD
Vandetanib—KDR—trachea—esophageal cancer	0.000525	0.00614	CbGeAlD
Vandetanib—Torsade de pointes—Capecitabine—esophageal cancer	0.000521	0.00602	CcSEcCtD
Vandetanib—Ileus—Capecitabine—esophageal cancer	0.000516	0.00596	CcSEcCtD
Vandetanib—Pain—Carboplatin—esophageal cancer	0.000516	0.00595	CcSEcCtD
Vandetanib—PDGFRB—epithelium—esophageal cancer	0.000514	0.00601	CbGeAlD
Vandetanib—MKNK1—lung—esophageal cancer	0.000513	0.006	CbGeAlD
Vandetanib—Erlotinib—NR1I2—esophageal cancer	0.000511	0.0626	CrCbGaD
Vandetanib—YES1—digestive system—esophageal cancer	0.000511	0.00597	CbGeAlD
Vandetanib—Laryngitis—Capecitabine—esophageal cancer	0.000507	0.00585	CcSEcCtD
Vandetanib—FGR—lung—esophageal cancer	0.000507	0.00593	CbGeAlD
Vandetanib—LCK—lung—esophageal cancer	0.000507	0.00593	CbGeAlD
Vandetanib—PDGFRB—bronchus—esophageal cancer	0.000506	0.00592	CbGeAlD
Vandetanib—STK10—digestive system—esophageal cancer	0.000506	0.00592	CbGeAlD
Vandetanib—AXL—lung—esophageal cancer	0.000505	0.0059	CbGeAlD
Vandetanib—BMPR1B—lymph node—esophageal cancer	0.000498	0.00583	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—esophageal cancer	0.000495	0.00579	CbGeAlD
Vandetanib—Haemoptysis—Capecitabine—esophageal cancer	0.000494	0.0057	CcSEcCtD
Vandetanib—Mucosal inflammation—Methotrexate—esophageal cancer	0.000491	0.00567	CcSEcCtD
Vandetanib—SRC—digestive system—esophageal cancer	0.000491	0.00575	CbGeAlD
Vandetanib—FMO3—lung—esophageal cancer	0.00049	0.00573	CbGeAlD
Vandetanib—SLK—lung—esophageal cancer	0.000486	0.00568	CbGeAlD
Vandetanib—Body temperature increased—Carboplatin—esophageal cancer	0.000477	0.0055	CcSEcCtD
Vandetanib—Fungal infection—Capecitabine—esophageal cancer	0.000473	0.00546	CcSEcCtD
Vandetanib—FYN—lung—esophageal cancer	0.000472	0.00553	CbGeAlD
Vandetanib—Skin ulcer—Capecitabine—esophageal cancer	0.000469	0.00542	CcSEcCtD
Vandetanib—TEK—lung—esophageal cancer	0.000462	0.0054	CbGeAlD
Vandetanib—MAP4K5—lung—esophageal cancer	0.000462	0.0054	CbGeAlD
Vandetanib—Erlotinib—ABL1—esophageal cancer	0.000456	0.0558	CrCbGaD
Vandetanib—PDGFRB—trachea—esophageal cancer	0.000455	0.00532	CbGeAlD
Vandetanib—KDR—digestive system—esophageal cancer	0.000452	0.00528	CbGeAlD
Vandetanib—ABL1—bronchus—esophageal cancer	0.000451	0.00528	CbGeAlD
Vandetanib—Polyp—Methotrexate—esophageal cancer	0.000447	0.00516	CcSEcCtD
Vandetanib—ABL1—smooth muscle tissue—esophageal cancer	0.000441	0.00516	CbGeAlD
Vandetanib—EPHB6—lung—esophageal cancer	0.000441	0.00516	CbGeAlD
Vandetanib—Gefitinib—CHEK2—esophageal cancer	0.000434	0.0532	CrCbGaD
Vandetanib—Folliculitis—Methotrexate—esophageal cancer	0.000433	0.005	CcSEcCtD
Vandetanib—FLT3—lymph node—esophageal cancer	0.000432	0.00506	CbGeAlD
Vandetanib—Bosutinib—CHEK2—esophageal cancer	0.000427	0.0523	CrCbGaD
Vandetanib—YES1—lung—esophageal cancer	0.000426	0.00499	CbGeAlD
Vandetanib—STK35—lymph node—esophageal cancer	0.000424	0.00495	CbGeAlD
Vandetanib—STK10—lung—esophageal cancer	0.000423	0.00494	CbGeAlD
Vandetanib—Nail disorder—Methotrexate—esophageal cancer	0.000419	0.00484	CcSEcCtD
Vandetanib—Proteinuria—Capecitabine—esophageal cancer	0.000416	0.0048	CcSEcCtD
Vandetanib—ABL2—lymph node—esophageal cancer	0.000413	0.00483	CbGeAlD
Vandetanib—SRC—lung—esophageal cancer	0.00041	0.0048	CbGeAlD
Vandetanib—Protein urine present—Capecitabine—esophageal cancer	0.00041	0.00474	CcSEcCtD
Vandetanib—Cyst—Methotrexate—esophageal cancer	0.000407	0.0047	CcSEcCtD
Vandetanib—ABL1—trachea—esophageal cancer	0.000405	0.00474	CbGeAlD
Vandetanib—EGFR—lymph node—esophageal cancer	0.000403	0.00471	CbGeAlD
Vandetanib—Cellulitis—Capecitabine—esophageal cancer	0.000402	0.00464	CcSEcCtD
Vandetanib—Hypocalcaemia—Capecitabine—esophageal cancer	0.000399	0.00461	CcSEcCtD
Vandetanib—FLT4—lymph node—esophageal cancer	0.000393	0.00459	CbGeAlD
Vandetanib—Afatinib—EGFR—esophageal cancer	0.000392	0.0481	CrCbGaD
Vandetanib—PDGFRB—digestive system—esophageal cancer	0.000391	0.00457	CbGeAlD
Vandetanib—RIPK2—lymph node—esophageal cancer	0.000391	0.00457	CbGeAlD
Vandetanib—VEGFA—lymph node—esophageal cancer	0.000389	0.00456	CbGeAlD
Vandetanib—FMO1—lymph node—esophageal cancer	0.000387	0.00453	CbGeAlD
Vandetanib—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000386	0.00446	CcSEcCtD
Vandetanib—Interstitial lung disease—Methotrexate—esophageal cancer	0.000384	0.00444	CcSEcCtD
Vandetanib—Cataract—Capecitabine—esophageal cancer	0.000384	0.00443	CcSEcCtD
Vandetanib—IRAK4—lymph node—esophageal cancer	0.000381	0.00446	CbGeAlD
Vandetanib—KDR—lung—esophageal cancer	0.000377	0.00441	CbGeAlD
Vandetanib—MAP2K5—lung—esophageal cancer	0.000377	0.00441	CbGeAlD
Vandetanib—ERBB3—lymph node—esophageal cancer	0.000374	0.00437	CbGeAlD
Vandetanib—Hyponatraemia—Cisplatin—esophageal cancer	0.000361	0.00417	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00036	0.00415	CcSEcCtD
Vandetanib—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000353	0.00407	CcSEcCtD
Vandetanib—Fungal infection—Methotrexate—esophageal cancer	0.000352	0.00407	CcSEcCtD
Vandetanib—MKNK1—lymph node—esophageal cancer	0.000351	0.0041	CbGeAlD
Vandetanib—Colitis—Capecitabine—esophageal cancer	0.000351	0.00405	CcSEcCtD
Vandetanib—Skin ulcer—Methotrexate—esophageal cancer	0.000349	0.00403	CcSEcCtD
Vandetanib—ABL1—digestive system—esophageal cancer	0.000349	0.00408	CbGeAlD
Vandetanib—LCK—lymph node—esophageal cancer	0.000347	0.00405	CbGeAlD
Vandetanib—RET—lymph node—esophageal cancer	0.000347	0.00405	CbGeAlD
Vandetanib—FGR—lymph node—esophageal cancer	0.000347	0.00405	CbGeAlD
Vandetanib—AXL—lymph node—esophageal cancer	0.000345	0.00404	CbGeAlD
Vandetanib—ABCC1—bronchus—esophageal cancer	0.000344	0.00402	CbGeAlD
Vandetanib—Dry eye—Capecitabine—esophageal cancer	0.000337	0.0039	CcSEcCtD
Vandetanib—Blood creatinine increased—Cisplatin—esophageal cancer	0.000337	0.00389	CcSEcCtD
Vandetanib—FMO3—lymph node—esophageal cancer	0.000335	0.00392	CbGeAlD
Vandetanib—Dehydration—Cisplatin—esophageal cancer	0.000335	0.00386	CcSEcCtD
Vandetanib—SLK—lymph node—esophageal cancer	0.000332	0.00389	CbGeAlD
Vandetanib—Neoplasm—Capecitabine—esophageal cancer	0.00033	0.00381	CcSEcCtD
Vandetanib—Hypokalaemia—Cisplatin—esophageal cancer	0.000327	0.00378	CcSEcCtD
Vandetanib—PDGFRB—lung—esophageal cancer	0.000327	0.00382	CbGeAlD
Vandetanib—FYN—lymph node—esophageal cancer	0.000323	0.00378	CbGeAlD
Vandetanib—Nasopharyngitis—Cisplatin—esophageal cancer	0.000322	0.00371	CcSEcCtD
Vandetanib—Sepsis—Capecitabine—esophageal cancer	0.000317	0.00366	CcSEcCtD
Vandetanib—TEK—lymph node—esophageal cancer	0.000316	0.00369	CbGeAlD
Vandetanib—MAP4K5—lymph node—esophageal cancer	0.000316	0.00369	CbGeAlD
Vandetanib—Proteinuria—Methotrexate—esophageal cancer	0.00031	0.00357	CcSEcCtD
Vandetanib—ABCC1—trachea—esophageal cancer	0.000309	0.00361	CbGeAlD
Vandetanib—ORM1—lung—esophageal cancer	0.000306	0.00358	CbGeAlD
Vandetanib—Protein urine present—Methotrexate—esophageal cancer	0.000305	0.00352	CcSEcCtD
Vandetanib—Pancreatitis—Cisplatin—esophageal cancer	0.000305	0.00352	CcSEcCtD
Vandetanib—EPHB6—lymph node—esophageal cancer	0.000302	0.00353	CbGeAlD
Vandetanib—Gastroenteritis—Capecitabine—esophageal cancer	0.000299	0.00346	CcSEcCtD
Vandetanib—Erlotinib—CYP1B1—esophageal cancer	0.000294	0.036	CrCbGaD
Vandetanib—YES1—lymph node—esophageal cancer	0.000292	0.00341	CbGeAlD
Vandetanib—ABL1—lung—esophageal cancer	0.000291	0.00341	CbGeAlD
Vandetanib—STK10—lymph node—esophageal cancer	0.000289	0.00338	CbGeAlD
Vandetanib—Bosutinib—ABL1—esophageal cancer	0.000281	0.0344	CrCbGaD
Vandetanib—SRC—lymph node—esophageal cancer	0.000281	0.00328	CbGeAlD
Vandetanib—Atrial fibrillation—Capecitabine—esophageal cancer	0.00028	0.00323	CcSEcCtD
Vandetanib—Dermatitis bullous—Capecitabine—esophageal cancer	0.000278	0.0032	CcSEcCtD
Vandetanib—Erlotinib—EGFR—esophageal cancer	0.000277	0.0339	CrCbGaD
Vandetanib—Respiratory failure—Methotrexate—esophageal cancer	0.000277	0.0032	CcSEcCtD
Vandetanib—Renal failure—Cisplatin—esophageal cancer	0.000273	0.00315	CcSEcCtD
Vandetanib—Cardiac failure—Capecitabine—esophageal cancer	0.000272	0.00314	CcSEcCtD
Vandetanib—Lethargy—Capecitabine—esophageal cancer	0.000271	0.00313	CcSEcCtD
Vandetanib—Stomatitis—Cisplatin—esophageal cancer	0.00027	0.00312	CcSEcCtD
Vandetanib—Conjunctivitis—Cisplatin—esophageal cancer	0.00027	0.00311	CcSEcCtD
Vandetanib—Hyponatraemia—Capecitabine—esophageal cancer	0.000266	0.00307	CcSEcCtD
Vandetanib—Cystitis noninfective—Methotrexate—esophageal cancer	0.000266	0.00307	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000265	0.00306	CcSEcCtD
Vandetanib—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000263	0.00303	CcSEcCtD
Vandetanib—Cystitis—Methotrexate—esophageal cancer	0.000263	0.00303	CcSEcCtD
Vandetanib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000262	0.00303	CcSEcCtD
Vandetanib—KDR—lymph node—esophageal cancer	0.000258	0.00302	CbGeAlD
Vandetanib—MAP2K5—lymph node—esophageal cancer	0.000258	0.00302	CbGeAlD
Vandetanib—Bradycardia—Cisplatin—esophageal cancer	0.000253	0.00293	CcSEcCtD
Vandetanib—Cardiac arrest—Capecitabine—esophageal cancer	0.000252	0.00291	CcSEcCtD
Vandetanib—Blood creatinine increased—Capecitabine—esophageal cancer	0.000248	0.00287	CcSEcCtD
Vandetanib—Dehydration—Capecitabine—esophageal cancer	0.000247	0.00285	CcSEcCtD
Vandetanib—Bladder pain—Methotrexate—esophageal cancer	0.000246	0.00284	CcSEcCtD
Vandetanib—Neoplasm—Methotrexate—esophageal cancer	0.000246	0.00284	CcSEcCtD
Vandetanib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000246	0.00284	CcSEcCtD
Vandetanib—Urethral disorder—Cisplatin—esophageal cancer	0.000244	0.00282	CcSEcCtD
Vandetanib—Dry skin—Capecitabine—esophageal cancer	0.000243	0.00281	CcSEcCtD
Vandetanib—Hypokalaemia—Capecitabine—esophageal cancer	0.000241	0.00279	CcSEcCtD
Vandetanib—Visual impairment—Cisplatin—esophageal cancer	0.00024	0.00277	CcSEcCtD
Vandetanib—Nasopharyngitis—Capecitabine—esophageal cancer	0.000237	0.00274	CcSEcCtD
Vandetanib—Sepsis—Methotrexate—esophageal cancer	0.000236	0.00273	CcSEcCtD
Vandetanib—Gastritis—Capecitabine—esophageal cancer	0.000235	0.00271	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000234	0.0027	CcSEcCtD
Vandetanib—Eye disorder—Cisplatin—esophageal cancer	0.000233	0.00269	CcSEcCtD
Vandetanib—Cardiac disorder—Cisplatin—esophageal cancer	0.000231	0.00267	CcSEcCtD
Vandetanib—Dysphagia—Capecitabine—esophageal cancer	0.000229	0.00265	CcSEcCtD
Vandetanib—Influenza—Capecitabine—esophageal cancer	0.000229	0.00265	CcSEcCtD
Vandetanib—Bronchospasm—Capecitabine—esophageal cancer	0.000225	0.0026	CcSEcCtD
Vandetanib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000224	0.00259	CcSEcCtD
Vandetanib—PDGFRB—lymph node—esophageal cancer	0.000223	0.00261	CbGeAlD
Vandetanib—Arrhythmia—Cisplatin—esophageal cancer	0.000222	0.00257	CcSEcCtD
Vandetanib—ABCC1—lung—esophageal cancer	0.000222	0.00259	CbGeAlD
Vandetanib—Bronchitis—Capecitabine—esophageal cancer	0.00022	0.00255	CcSEcCtD
Vandetanib—Alopecia—Cisplatin—esophageal cancer	0.00022	0.00254	CcSEcCtD
Vandetanib—Malnutrition—Cisplatin—esophageal cancer	0.000217	0.0025	CcSEcCtD
Vandetanib—Neutropenia—Capecitabine—esophageal cancer	0.000214	0.00248	CcSEcCtD
Vandetanib—Dysuria—Capecitabine—esophageal cancer	0.000214	0.00248	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000213	0.00246	CcSEcCtD
Vandetanib—ORM1—lymph node—esophageal cancer	0.00021	0.00245	CbGeAlD
Vandetanib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000209	0.00242	CcSEcCtD
Vandetanib—Muscle spasms—Cisplatin—esophageal cancer	0.000208	0.00241	CcSEcCtD
Vandetanib—Weight decreased—Capecitabine—esophageal cancer	0.000207	0.00239	CcSEcCtD
Vandetanib—Hyperglycaemia—Capecitabine—esophageal cancer	0.000207	0.00239	CcSEcCtD
Vandetanib—Pneumonia—Capecitabine—esophageal cancer	0.000206	0.00237	CcSEcCtD
Vandetanib—Infestation—Capecitabine—esophageal cancer	0.000204	0.00236	CcSEcCtD
Vandetanib—Infestation NOS—Capecitabine—esophageal cancer	0.000204	0.00236	CcSEcCtD
Vandetanib—Vision blurred—Cisplatin—esophageal cancer	0.000204	0.00236	CcSEcCtD
Vandetanib—Depression—Capecitabine—esophageal cancer	0.000204	0.00235	CcSEcCtD
Vandetanib—Tremor—Cisplatin—esophageal cancer	0.000203	0.00234	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000203	0.00234	CcSEcCtD
Vandetanib—Lethargy—Methotrexate—esophageal cancer	0.000201	0.00233	CcSEcCtD
Vandetanib—Renal failure—Capecitabine—esophageal cancer	0.000201	0.00232	CcSEcCtD
Vandetanib—Stomatitis—Capecitabine—esophageal cancer	0.000199	0.0023	CcSEcCtD
Vandetanib—ABL1—lymph node—esophageal cancer	0.000199	0.00233	CbGeAlD
Vandetanib—Conjunctivitis—Capecitabine—esophageal cancer	0.000199	0.00229	CcSEcCtD
Vandetanib—Urinary tract infection—Capecitabine—esophageal cancer	0.000199	0.00229	CcSEcCtD
Vandetanib—Haematuria—Capecitabine—esophageal cancer	0.000195	0.00225	CcSEcCtD
Vandetanib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000193	0.00223	CcSEcCtD
Vandetanib—Epistaxis—Capecitabine—esophageal cancer	0.000193	0.00223	CcSEcCtD
Vandetanib—Convulsion—Cisplatin—esophageal cancer	0.000188	0.00217	CcSEcCtD
Vandetanib—Bradycardia—Capecitabine—esophageal cancer	0.000187	0.00216	CcSEcCtD
Vandetanib—Haemoglobin—Capecitabine—esophageal cancer	0.000184	0.00213	CcSEcCtD
Vandetanib—Anxiety—Cisplatin—esophageal cancer	0.000184	0.00212	CcSEcCtD
Vandetanib—ALB—lymph node—esophageal cancer	0.000184	0.00215	CbGeAlD
Vandetanib—ABCG2—lung—esophageal cancer	0.000184	0.00215	CbGeAlD
Vandetanib—Haemorrhage—Capecitabine—esophageal cancer	0.000183	0.00212	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000183	0.00212	CcSEcCtD
Vandetanib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000181	0.00209	CcSEcCtD
Vandetanib—Urethral disorder—Capecitabine—esophageal cancer	0.00018	0.00208	CcSEcCtD
Vandetanib—Oedema—Cisplatin—esophageal cancer	0.000177	0.00204	CcSEcCtD
Vandetanib—Visual impairment—Capecitabine—esophageal cancer	0.000177	0.00204	CcSEcCtD
Vandetanib—Infection—Cisplatin—esophageal cancer	0.000176	0.00203	CcSEcCtD
Vandetanib—Erythema multiforme—Capecitabine—esophageal cancer	0.000173	0.002	CcSEcCtD
Vandetanib—Gefitinib—EGFR—esophageal cancer	0.000173	0.0212	CrCbGaD
Vandetanib—Nervous system disorder—Cisplatin—esophageal cancer	0.000173	0.002	CcSEcCtD
Vandetanib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000173	0.002	CcSEcCtD
Vandetanib—Skin disorder—Cisplatin—esophageal cancer	0.000172	0.00198	CcSEcCtD
Vandetanib—Eye disorder—Capecitabine—esophageal cancer	0.000171	0.00198	CcSEcCtD
Vandetanib—Bosutinib—EGFR—esophageal cancer	0.000171	0.0209	CrCbGaD
Vandetanib—Cardiac disorder—Capecitabine—esophageal cancer	0.00017	0.00197	CcSEcCtD
Vandetanib—Pancreatitis—Methotrexate—esophageal cancer	0.000167	0.00193	CcSEcCtD
Vandetanib—Angiopathy—Capecitabine—esophageal cancer	0.000166	0.00192	CcSEcCtD
Vandetanib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000165	0.00191	CcSEcCtD
Vandetanib—Arrhythmia—Capecitabine—esophageal cancer	0.000164	0.00189	CcSEcCtD
Vandetanib—Alopecia—Capecitabine—esophageal cancer	0.000162	0.00187	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000161	0.00186	CcSEcCtD
Vandetanib—Mental disorder—Capecitabine—esophageal cancer	0.000161	0.00186	CcSEcCtD
Vandetanib—Malnutrition—Capecitabine—esophageal cancer	0.00016	0.00184	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—esophageal cancer	0.00016	0.00184	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—esophageal cancer	0.00016	0.00184	CcSEcCtD
Vandetanib—Paraesthesia—Cisplatin—esophageal cancer	0.000159	0.00183	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000159	0.00183	CcSEcCtD
Vandetanib—Dyspnoea—Cisplatin—esophageal cancer	0.000158	0.00182	CcSEcCtD
Vandetanib—Dysgeusia—Capecitabine—esophageal cancer	0.000156	0.00181	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000156	0.0018	CcSEcCtD
Vandetanib—Decreased appetite—Cisplatin—esophageal cancer	0.000154	0.00177	CcSEcCtD
Vandetanib—Muscle spasms—Capecitabine—esophageal cancer	0.000154	0.00177	CcSEcCtD
Vandetanib—CYP3A4—digestive system—esophageal cancer	0.000153	0.00179	CbGeAlD
Vandetanib—Pneumonia—Methotrexate—esophageal cancer	0.000153	0.00177	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000153	0.00176	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—esophageal cancer	0.000152	0.00176	CcSEcCtD
Vandetanib—Infestation—Methotrexate—esophageal cancer	0.000152	0.00176	CcSEcCtD
Vandetanib—Depression—Methotrexate—esophageal cancer	0.000152	0.00175	CcSEcCtD
Vandetanib—ABCC1—lymph node—esophageal cancer	0.000152	0.00177	CbGeAlD
Vandetanib—Pain—Cisplatin—esophageal cancer	0.000151	0.00175	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000151	0.00174	CcSEcCtD
Vandetanib—Vision blurred—Capecitabine—esophageal cancer	0.000151	0.00174	CcSEcCtD
Vandetanib—Tremor—Capecitabine—esophageal cancer	0.00015	0.00173	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—esophageal cancer	0.00015	0.00173	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—esophageal cancer	0.000148	0.00171	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—esophageal cancer	0.000148	0.00171	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—esophageal cancer	0.000145	0.00168	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000144	0.00166	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—esophageal cancer	0.000144	0.00166	CcSEcCtD
Vandetanib—Loss of consciousness—Capecitabine—esophageal cancer	0.00014	0.00162	CcSEcCtD
Vandetanib—Body temperature increased—Cisplatin—esophageal cancer	0.00014	0.00161	CcSEcCtD
Vandetanib—Cough—Capecitabine—esophageal cancer	0.000139	0.00161	CcSEcCtD
Vandetanib—Hypertension—Capecitabine—esophageal cancer	0.000138	0.00159	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—esophageal cancer	0.000137	0.00159	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—esophageal cancer	0.000137	0.00158	CcSEcCtD
Vandetanib—Chest pain—Capecitabine—esophageal cancer	0.000136	0.00157	CcSEcCtD
Vandetanib—Arthralgia—Capecitabine—esophageal cancer	0.000136	0.00157	CcSEcCtD
Vandetanib—Anxiety—Capecitabine—esophageal cancer	0.000136	0.00156	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000135	0.00156	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000135	0.00156	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—esophageal cancer	0.000134	0.00155	CcSEcCtD
Vandetanib—Dry mouth—Capecitabine—esophageal cancer	0.000133	0.00154	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—esophageal cancer	0.000132	0.00152	CcSEcCtD
Vandetanib—Oedema—Capecitabine—esophageal cancer	0.00013	0.00151	CcSEcCtD
Vandetanib—Infection—Capecitabine—esophageal cancer	0.00013	0.0015	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—esophageal cancer	0.000129	0.00149	CcSEcCtD
Vandetanib—Nervous system disorder—Capecitabine—esophageal cancer	0.000128	0.00148	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—esophageal cancer	0.000128	0.00147	CcSEcCtD
Vandetanib—Thrombocytopenia—Capecitabine—esophageal cancer	0.000128	0.00147	CcSEcCtD
Vandetanib—Asthenia—Cisplatin—esophageal cancer	0.000127	0.00147	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—esophageal cancer	0.000127	0.00146	CcSEcCtD
Vandetanib—Skin disorder—Capecitabine—esophageal cancer	0.000127	0.00146	CcSEcCtD
Vandetanib—ABCG2—lymph node—esophageal cancer	0.000126	0.00147	CbGeAlD
Vandetanib—Angiopathy—Methotrexate—esophageal cancer	0.000124	0.00143	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000123	0.00142	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—esophageal cancer	0.000121	0.0014	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—esophageal cancer	0.000121	0.00139	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—esophageal cancer	0.00012	0.00138	CcSEcCtD
Vandetanib—Afatinib—ABCB1—esophageal cancer	0.000119	0.0146	CrCbGaD
Vandetanib—Malnutrition—Methotrexate—esophageal cancer	0.000119	0.00137	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000119	0.00137	CcSEcCtD
Vandetanib—Insomnia—Capecitabine—esophageal cancer	0.000118	0.00136	CcSEcCtD
Vandetanib—Paraesthesia—Capecitabine—esophageal cancer	0.000117	0.00135	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—esophageal cancer	0.000116	0.00134	CcSEcCtD
Vandetanib—Dyspnoea—Capecitabine—esophageal cancer	0.000116	0.00134	CcSEcCtD
Vandetanib—Dyspepsia—Capecitabine—esophageal cancer	0.000115	0.00132	CcSEcCtD
Vandetanib—Decreased appetite—Capecitabine—esophageal cancer	0.000113	0.00131	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000113	0.0013	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—esophageal cancer	0.000112	0.0013	CcSEcCtD
Vandetanib—Fatigue—Capecitabine—esophageal cancer	0.000112	0.0013	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—esophageal cancer	0.000112	0.00129	CcSEcCtD
Vandetanib—Rash—Cisplatin—esophageal cancer	0.000112	0.00129	CcSEcCtD
Vandetanib—Constipation—Capecitabine—esophageal cancer	0.000111	0.00129	CcSEcCtD
Vandetanib—Pain—Capecitabine—esophageal cancer	0.000111	0.00129	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—esophageal cancer	0.000111	0.00129	CcSEcCtD
Vandetanib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000107	0.00123	CcSEcCtD
Vandetanib—Nausea—Cisplatin—esophageal cancer	0.000105	0.00121	CcSEcCtD
Vandetanib—Cough—Methotrexate—esophageal cancer	0.000104	0.0012	CcSEcCtD
Vandetanib—Abdominal pain—Capecitabine—esophageal cancer	0.000103	0.00119	CcSEcCtD
Vandetanib—Body temperature increased—Capecitabine—esophageal cancer	0.000103	0.00119	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—esophageal cancer	0.000103	0.00119	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—esophageal cancer	0.000101	0.00117	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—esophageal cancer	0.000101	0.00117	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000101	0.00116	CcSEcCtD
Vandetanib—Infection—Methotrexate—esophageal cancer	9.64e-05	0.00111	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—esophageal cancer	9.52e-05	0.0011	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—esophageal cancer	9.5e-05	0.0011	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—esophageal cancer	9.43e-05	0.00109	CcSEcCtD
Vandetanib—Asthenia—Capecitabine—esophageal cancer	9.35e-05	0.00108	CcSEcCtD
Vandetanib—Pruritus—Capecitabine—esophageal cancer	9.22e-05	0.00106	CcSEcCtD
Vandetanib—Diarrhoea—Capecitabine—esophageal cancer	8.92e-05	0.00103	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	8.84e-05	0.00102	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—esophageal cancer	8.78e-05	0.00101	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—esophageal cancer	8.71e-05	0.00101	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—esophageal cancer	8.65e-05	0.000999	CcSEcCtD
Vandetanib—Dizziness—Capecitabine—esophageal cancer	8.62e-05	0.000995	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—esophageal cancer	8.54e-05	0.000986	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—esophageal cancer	8.44e-05	0.000974	CcSEcCtD
Vandetanib—Erlotinib—ABCB1—esophageal cancer	8.43e-05	0.0103	CrCbGaD
Vandetanib—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.38e-05	0.000967	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—esophageal cancer	8.37e-05	0.000966	CcSEcCtD
Vandetanib—Pain—Methotrexate—esophageal cancer	8.3e-05	0.000958	CcSEcCtD
Vandetanib—Vomiting—Capecitabine—esophageal cancer	8.29e-05	0.000957	CcSEcCtD
Vandetanib—Rash—Capecitabine—esophageal cancer	8.22e-05	0.000949	CcSEcCtD
Vandetanib—Dermatitis—Capecitabine—esophageal cancer	8.21e-05	0.000948	CcSEcCtD
Vandetanib—Headache—Capecitabine—esophageal cancer	8.17e-05	0.000943	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—esophageal cancer	7.94e-05	0.000916	CcSEcCtD
Vandetanib—Nausea—Capecitabine—esophageal cancer	7.74e-05	0.000894	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—esophageal cancer	7.67e-05	0.000886	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—esophageal cancer	7.67e-05	0.000886	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—esophageal cancer	6.96e-05	0.000804	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—esophageal cancer	6.87e-05	0.000793	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—esophageal cancer	6.64e-05	0.000767	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—esophageal cancer	6.42e-05	0.000741	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—esophageal cancer	6.17e-05	0.000712	CcSEcCtD
Vandetanib—Rash—Methotrexate—esophageal cancer	6.12e-05	0.000706	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—esophageal cancer	6.11e-05	0.000706	CcSEcCtD
Vandetanib—Headache—Methotrexate—esophageal cancer	6.08e-05	0.000702	CcSEcCtD
Vandetanib—Nausea—Methotrexate—esophageal cancer	5.76e-05	0.000666	CcSEcCtD
Vandetanib—Gefitinib—ABCB1—esophageal cancer	5.27e-05	0.00646	CrCbGaD
Vandetanib—Bosutinib—ABCB1—esophageal cancer	5.19e-05	0.00636	CrCbGaD
Vandetanib—EGFR—Innate Immune System—PIK3CA—esophageal cancer	2.59e-06	1.51e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CDKN1A—esophageal cancer	2.58e-06	1.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—BCL2—esophageal cancer	2.58e-06	1.5e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CDKN1A—esophageal cancer	2.57e-06	1.5e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CCND1—esophageal cancer	2.57e-06	1.5e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CASP8—esophageal cancer	2.56e-06	1.49e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NOTCH1—esophageal cancer	2.56e-06	1.49e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ERBB2—esophageal cancer	2.55e-06	1.49e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CREBBP—esophageal cancer	2.55e-06	1.49e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EGFR—esophageal cancer	2.54e-06	1.48e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CDKN1A—esophageal cancer	2.52e-06	1.47e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CDKN1A—esophageal cancer	2.51e-06	1.46e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOTCH1—esophageal cancer	2.51e-06	1.46e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CDKN1A—esophageal cancer	2.5e-06	1.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ERBB2—esophageal cancer	2.5e-06	1.46e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—PIK3CA—esophageal cancer	2.5e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—PIK3CA—esophageal cancer	2.49e-06	1.45e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CDKN1A—esophageal cancer	2.49e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—BCL2—esophageal cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—PIK3CA—esophageal cancer	2.48e-06	1.45e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CDKN1A—esophageal cancer	2.48e-06	1.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS3—esophageal cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOTCH1—esophageal cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SMAD4—esophageal cancer	2.47e-06	1.44e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EP300—esophageal cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CREBBP—esophageal cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—ERBB2—esophageal cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—PIK3CA—esophageal cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.45e-06	1.43e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.45e-06	1.42e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EP300—esophageal cancer	2.45e-06	1.42e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—EGFR—esophageal cancer	2.44e-06	1.42e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP1B1—esophageal cancer	2.42e-06	1.41e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—ERBB2—esophageal cancer	2.41e-06	1.41e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—esophageal cancer	2.4e-06	1.4e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EP300—esophageal cancer	2.39e-06	1.39e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—PIK3CA—esophageal cancer	2.39e-06	1.39e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EP300—esophageal cancer	2.39e-06	1.39e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EP300—esophageal cancer	2.38e-06	1.39e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS3—esophageal cancer	2.38e-06	1.39e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—PIK3CA—esophageal cancer	2.38e-06	1.38e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CDKN1A—esophageal cancer	2.37e-06	1.38e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—esophageal cancer	2.37e-06	1.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HIF1A—esophageal cancer	2.37e-06	1.38e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EP300—esophageal cancer	2.37e-06	1.38e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EP300—esophageal cancer	2.36e-06	1.37e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CREBBP—esophageal cancer	2.36e-06	1.37e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMP—esophageal cancer	2.34e-06	1.36e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MYC—esophageal cancer	2.34e-06	1.36e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCND1—esophageal cancer	2.33e-06	1.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CREBBP—esophageal cancer	2.32e-06	1.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—ERBB2—esophageal cancer	2.31e-06	1.35e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CDKN1A—esophageal cancer	2.29e-06	1.33e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EGFR—esophageal cancer	2.29e-06	1.33e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HIF1A—esophageal cancer	2.28e-06	1.33e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP19A1—esophageal cancer	2.28e-06	1.32e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.27e-06	1.32e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CREBBP—esophageal cancer	2.27e-06	1.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KDR—esophageal cancer	2.26e-06	1.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—esophageal cancer	2.26e-06	1.32e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CDKN1A—esophageal cancer	2.26e-06	1.32e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EP300—esophageal cancer	2.26e-06	1.31e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCND1—esophageal cancer	2.26e-06	1.31e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CREBBP—esophageal cancer	2.24e-06	1.3e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—EP300—esophageal cancer	2.24e-06	1.3e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—ERBB2—esophageal cancer	2.23e-06	1.3e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.22e-06	1.29e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—PIK3CA—esophageal cancer	2.21e-06	1.28e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—BCL2—esophageal cancer	2.2e-06	1.28e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—NOS3—esophageal cancer	2.2e-06	1.28e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CDKN1A—esophageal cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KDR—esophageal cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—esophageal cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EP300—esophageal cancer	2.18e-06	1.27e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CREBBP—esophageal cancer	2.16e-06	1.26e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EP300—esophageal cancer	2.15e-06	1.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CDKN1A—esophageal cancer	2.14e-06	1.25e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	2.14e-06	1.24e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ERBB2—esophageal cancer	2.14e-06	1.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOTCH1—esophageal cancer	2.13e-06	1.24e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—PIK3CA—esophageal cancer	2.12e-06	1.23e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TPI1—esophageal cancer	2.11e-06	1.23e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.11e-06	1.23e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS3—esophageal cancer	2.11e-06	1.23e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CDKN1A—esophageal cancer	2.1e-06	1.22e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	2.09e-06	1.22e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—esophageal cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MYC—esophageal cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HMOX1—esophageal cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EP300—esophageal cancer	2.08e-06	1.21e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CDKN1A—esophageal cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MYC—esophageal cancer	2.06e-06	1.2e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	2.05e-06	1.2e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—esophageal cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—esophageal cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—EP300—esophageal cancer	2.04e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOS3—esophageal cancer	2.04e-06	1.18e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—esophageal cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.03e-06	1.18e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HIF1A—esophageal cancer	2.02e-06	1.18e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—esophageal cancer	2.02e-06	1.17e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—esophageal cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—esophageal cancer	2.01e-06	1.17e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOS3—esophageal cancer	2e-06	1.17e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EP300—esophageal cancer	1.99e-06	1.16e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCB1—esophageal cancer	1.99e-06	1.16e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—PIK3CA—esophageal cancer	1.98e-06	1.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CDKN1A—esophageal cancer	1.98e-06	1.15e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—ERBB2—esophageal cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—esophageal cancer	1.97e-06	1.15e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EP300—esophageal cancer	1.96e-06	1.14e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.95e-06	1.14e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	1.94e-06	1.13e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.93e-06	1.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CREBBP—esophageal cancer	1.93e-06	1.13e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—esophageal cancer	1.93e-06	1.13e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KDR—esophageal cancer	1.93e-06	1.12e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—esophageal cancer	1.93e-06	1.12e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—esophageal cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—esophageal cancer	1.92e-06	1.12e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CDKN1A—esophageal cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ERBB2—esophageal cancer	1.9e-06	1.11e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—esophageal cancer	1.9e-06	1.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—EP300—esophageal cancer	1.88e-06	1.09e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ERBB2—esophageal cancer	1.87e-06	1.09e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—esophageal cancer	1.87e-06	1.09e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CREBBP—esophageal cancer	1.86e-06	1.08e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—esophageal cancer	1.85e-06	1.08e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNG7—esophageal cancer	1.84e-06	1.07e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—esophageal cancer	1.83e-06	1.07e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CDKN1A—esophageal cancer	1.83e-06	1.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOTCH1—esophageal cancer	1.82e-06	1.06e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	1.82e-06	1.06e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EP300—esophageal cancer	1.81e-06	1.06e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—esophageal cancer	1.81e-06	1.05e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PIK3CA—esophageal cancer	1.81e-06	1.05e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—esophageal cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—esophageal cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—esophageal cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—esophageal cancer	1.77e-06	1.03e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—esophageal cancer	1.76e-06	1.03e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	1.76e-06	1.02e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—esophageal cancer	1.75e-06	1.02e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—esophageal cancer	1.74e-06	1.02e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—esophageal cancer	1.74e-06	1.01e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EP300—esophageal cancer	1.74e-06	1.01e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—esophageal cancer	1.73e-06	1.01e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.72e-06	1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	1.72e-06	1e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—esophageal cancer	1.71e-06	9.96e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—esophageal cancer	1.7e-06	9.9e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—esophageal cancer	1.69e-06	9.86e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—CDKN1A—esophageal cancer	1.69e-06	9.82e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—esophageal cancer	1.68e-06	9.79e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—esophageal cancer	1.67e-06	9.74e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—EP300—esophageal cancer	1.67e-06	9.73e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—esophageal cancer	1.67e-06	9.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—esophageal cancer	1.67e-06	9.71e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	1.66e-06	9.68e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—esophageal cancer	1.66e-06	9.64e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—esophageal cancer	1.65e-06	9.64e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CREBBP—esophageal cancer	1.65e-06	9.6e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—esophageal cancer	1.65e-06	9.6e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.64e-06	9.55e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—esophageal cancer	1.64e-06	9.54e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—esophageal cancer	1.63e-06	9.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.62e-06	9.44e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—esophageal cancer	1.62e-06	9.43e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—esophageal cancer	1.61e-06	9.37e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—esophageal cancer	1.6e-06	9.34e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—esophageal cancer	1.6e-06	9.33e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—esophageal cancer	1.6e-06	9.32e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—esophageal cancer	1.59e-06	9.26e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	1.58e-06	9.21e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—esophageal cancer	1.58e-06	9.19e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—esophageal cancer	1.56e-06	9.09e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—esophageal cancer	1.55e-06	9.01e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—esophageal cancer	1.54e-06	8.99e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—esophageal cancer	1.54e-06	8.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.54e-06	8.95e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.54e-06	8.95e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—esophageal cancer	1.54e-06	8.94e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—esophageal cancer	1.52e-06	8.87e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSME2—esophageal cancer	1.51e-06	8.82e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSME1—esophageal cancer	1.51e-06	8.82e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.51e-06	8.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—esophageal cancer	1.51e-06	8.77e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—esophageal cancer	1.49e-06	8.65e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—esophageal cancer	1.48e-06	8.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—esophageal cancer	1.48e-06	8.6e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—esophageal cancer	1.48e-06	8.59e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—esophageal cancer	1.47e-06	8.56e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—esophageal cancer	1.45e-06	8.45e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—esophageal cancer	1.43e-06	8.33e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—esophageal cancer	1.4e-06	8.14e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—esophageal cancer	1.39e-06	8.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—esophageal cancer	1.38e-06	8.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—esophageal cancer	1.38e-06	8.04e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—esophageal cancer	1.38e-06	8.03e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	1.38e-06	8.02e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—esophageal cancer	1.37e-06	7.96e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—esophageal cancer	1.35e-06	7.85e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	1.35e-06	7.85e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—esophageal cancer	1.34e-06	7.8e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	1.33e-06	7.76e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CREBBP—esophageal cancer	1.33e-06	7.76e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—esophageal cancer	1.33e-06	7.73e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—esophageal cancer	1.32e-06	7.68e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—esophageal cancer	1.32e-06	7.67e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.31e-06	7.61e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—esophageal cancer	1.3e-06	7.56e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—esophageal cancer	1.29e-06	7.48e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—esophageal cancer	1.27e-06	7.39e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—esophageal cancer	1.24e-06	7.2e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.23e-06	7.15e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—esophageal cancer	1.22e-06	7.11e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—esophageal cancer	1.19e-06	6.94e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—esophageal cancer	1.19e-06	6.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—esophageal cancer	1.18e-06	6.87e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	1.17e-06	6.81e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—esophageal cancer	1.15e-06	6.68e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—esophageal cancer	1.15e-06	6.67e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	1.13e-06	6.59e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—esophageal cancer	1.13e-06	6.56e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—esophageal cancer	1.12e-06	6.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.12e-06	6.53e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—esophageal cancer	1.11e-06	6.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—esophageal cancer	1.11e-06	6.44e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—esophageal cancer	1.09e-06	6.35e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—esophageal cancer	1.09e-06	6.35e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.09e-06	6.33e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—esophageal cancer	1.08e-06	6.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.08e-06	6.26e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—esophageal cancer	9.79e-07	5.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—esophageal cancer	9.74e-07	5.67e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—esophageal cancer	9.57e-07	5.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—esophageal cancer	9.42e-07	5.49e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	9.39e-07	5.47e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—esophageal cancer	9.08e-07	5.29e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—esophageal cancer	9.07e-07	5.28e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—esophageal cancer	8.31e-07	4.84e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—esophageal cancer	8.04e-07	4.68e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.19e-07	4.19e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—esophageal cancer	6.71e-07	3.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—esophageal cancer	6.44e-07	3.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—esophageal cancer	5.89e-07	3.43e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—esophageal cancer	4.9e-07	2.85e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.62e-07	2.11e-06	CbGpPWpGaD
